XOMA logo

XOMA
XOMA Corp

7,350
Mkt Cap
$523.59M
Volume
10,544.00
52W High
$42.81
52W Low
$22.29
PE Ratio
26.57
XOMA Fundamentals
Price
$41.84
Prev Close
$41.75
Open
$41.97
50D MA
$35.36
Beta
0.86
Avg. Volume
388,668.22
EPS (Annual)
$1.46
P/B
5.36
Rev/Employee
$3.72M
$541.03
Loading...
Loading...
News
all
press releases
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
Oncobiologics (OTLK) delivered earnings and revenue surprises of -33.33% and -97.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
More News
News Placeholder
Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?
Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders? Are XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 14, 2026 Insiders may stand to receive...
PR Newswire·4d ago
News Placeholder
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
Kyntra Bio (KYNB) delivered earnings and revenue surprises of -11.48% and +140.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders?
Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders? Are SEM, XOMA, SLNO, KORE Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 8, 2026 Insiders may stand to...
PR Newswire·10d ago
News Placeholder
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -23.33% and +80.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +10.59% and -86.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·11d ago
News Placeholder
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +64.91% and +9.64%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--HLX, OGN, XOMA, and RMAX PR Newswire NEW YORK, May 6, 2026 NEW YORK, May 6, 2026 /PRNewswire/ -- Class Action AttorneyJuan...
PR Newswire·12d ago
News Placeholder
XOMA Royalty (XOMA) Projected to Post Earnings on Tuesday
XOMA Royalty (NASDAQ:XOMA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...
MarketBeat·13d ago
News Placeholder
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, May 4, 2026 Insiders may stand to receive...
PR Newswire·14d ago
<
1
2
...
>

Latest XOMA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.